Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2019

View Archived Issues

Their antiviral work done, T cells go rogue

Clinical qualification of a novel P2X7-specific PET ligand in healthy volunteers

Phase III trial of tucidinostat/exemestane in advanced, HR-positive breast cancer

Sirona's SGLT2 inhibitor TFC-039 advancing through phase I trials

Protein provides protection against diabetic retinopathy

ADAMTS13 deficiency contributes to Alzheimer's disease cerebrovascular dysfunction

Phase II trial of axitinib plus pembrolizumab in patients with advanced sarcomas

Entera initiates phase II dose ranging study for oral PTH

University of Dundee and Bukwang Pharmaceutical partner to develop new treatment for PD

BST-236 demonstrates promising safety in patients with AML unfit for standard therapy

CARMIL2 variant linked to infantile onset of colitis and gastrointestinal eosinophilic disease

miRNAs and angiogenic factors as potential new biomarkers in CML

miR-451 is a potential therapeutic target for spinocerebellar ataxia type 2 treatment

FDA grants IND approval to novel PD-1/VEGF bispecific antibody for solid tumors

[177Lu]BL-01 as a radiotherapeutic agent for CXCR4-expressing lymphoma

Confo Therapeutics and DyNAbind establish GPCR drug discovery collaboration

European Commission approves Ultomiris for adults with PNH

FDA grants accelerated approval to Xpovio for relapsed refractory multiple myeloma

Synergys Biotherapeutics receives NCI funding for development of anti-HER2 antibody fusion candidate

Leo Pharma patents PDE4 inhibitors

GlaxoSmithKline identifies new IDO1 inhibitors for HIV infection

New PRMT5 inhibitors for cancer presented by Lupin

Gedeon Richter divulges vasopressin V1A receptor antagonists

VenatoRx Pharmaceuticals synthesizes HBV capsid assembly modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...